Brief: Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas’ Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting
14/05/2025 13:06
May 14 (Reuters) - Editas Medicine Inc EDIT.O: EDITAS MEDICINE REPORTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF EDITAS’ GENE UPREGULATION STRATEGY IN HSCS AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY ANNUAL MEETING Source text: ID:nGNX5qbdp1 Further company coverage: EDIT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering